Biotech Breakthroughs — March 24, 2026
This week in biotech, the FDA regulatory landscape dominated headlines as analysts mapped out key decisions expected in the post-Prasad era, while Theriva Biologics secured a pivotal FDA meeting clearing the path for a Phase 3 pancreatic cancer trial. Eisai and Biogen presented encouraging real-world data on the Alzheimer's drug lecanemab (Leqembi) at a major conference, and two new denosumab biosimilars won FDA approval — expanding access to treatment for osteoporosis and bone complications in cancer patients.
Biotech Breakthroughs — March 24, 2026
Top Breakthroughs
FDA Regulatory Outlook: Charting the Post-Prasad Era for Rare Disease Drugs
- Company/Institution: STAT News / Multiple companies under FDA review
- What happened: STAT News published an in-depth analysis tracking six drugmakers' prospects over six months as the FDA navigates its new regulatory posture following changes in its leadership. The piece identifies key signals of regulatory flexibility and what upcoming approval decisions will reveal about how the agency is approaching rare disease drugs.
- Why it matters: The post-Prasad FDA era represents a significant inflection point for biotech — particularly for companies pursuing rare disease indications where smaller trial sizes and surrogate endpoints are common. The decisions under scrutiny will set precedent for years to come.
- Stage: Regulatory analysis / multiple drugs under FDA review
statnews.com
Compass says its psilocybin drug helped patients with severe depression in two trials
FDA flashpoints to watch next year
The biotech scorecard for the first quarter: 26 stock-moving events to watch
Prime Medicine to seek approval for gene-editing treatment after two-patient trial
Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era
Theriva Biologics Wins Positive FDA End-of-Phase 2 Meeting for Pancreatic Cancer Therapy VCN-01
- Company/Institution: Theriva Biologics
- What happened: Theriva Biologics announced a successful End-of-Phase 2 meeting with the FDA regarding the design of a Phase 3 trial of VCN-01, an oncolytic adenovirus therapy, in combination with gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC).
- Why it matters: Metastatic PDAC carries one of the worst prognoses in oncology, with very limited treatment options. A successful FDA alignment on Phase 3 design clears a critical regulatory hurdle and signals the agency's confidence in the trial framework — a significant step toward a potential new therapeutic option for patients with this devastating disease.
- Stage: End of Phase 2 / entering Phase 3
FDA Approves Two New Denosumab Biosimilars
- Company/Institution: FDA / Multiple manufacturers (Targeted Oncology)
- What happened: The FDA granted approval to two new biosimilars of denosumab (brand name Prolia/Xgeva), expanding the competitive landscape for one of the most widely used drugs in bone health and oncology bone complications.
- Why it matters: Denosumab biosimilar approvals directly improve patient access by reducing cost barriers to a drug used for osteoporosis and cancer-related bone complications. With two new entrants, competitive pricing pressure is expected to benefit payers and patients alike.
- Stage: FDA approved
Clinical Trial Watch
-
Leqembi / lecanemab-irmb (Eisai / Biogen): Real-world, long-term treatment persistence data in U.S. patients presented at the AD/PD™ 2026 conference. The data covers actual clinical use since lecanemab's approval, offering early insight into how patients tolerate and persist on the drug outside of controlled trial settings.
-
VCN-01 (Theriva Biologics): Positive End-of-Phase 2 FDA meeting completed, enabling advancement into a proposed Phase 3 trial of VCN-01 combined with gemcitabine/nab-paclitaxel for first-line metastatic pancreatic ductal adenocarcinoma.
-
Multiple infectious disease and rare disease therapies (Various): ContagionLive published a roundup this week of infectious disease therapeutics and vaccines reporting Phase 3 data, beginning trials, or filing with regulatory agencies in 2026 — providing a forward-looking view of what trial readouts are imminent.
Research Frontiers
No peer-reviewed papers from Nature, Science, or bioRxiv with confirmed publication dates after 2026-03-17 were returned in this week's research results. The Nature and Science articles surfaced were from 2023–2025 and fall outside the coverage window. Verified fresh research findings will be included when available.
Deals & Business Moves
-
Kelun-Biotech: The Chinese biotech reported its 2025 annual results, citing revenue of approximately RMB 2,057.92 million and gross profit of approximately RMB 1,478.78 million — representing year-on-year growth. The company flagged a tiered pipeline ready for expansion with multiple products launched.
-
PolyPid: The company received a PDUFA fee waiver worth approximately $4.3 million from the FDA as a small business, for its D-PLEX₁₀₀ New Drug Application. PolyPid stated it remains on track to initiate the NDA submission by the end of this month, allowing it to focus resources on commercialization preparations.
Analysis: What to Watch Next
-
The FDA's regulatory philosophy is under a microscope. STAT News's "six drugmakers, six months" framework highlights that the next wave of FDA decisions for rare disease drugs will serve as a bellwether for how the agency balances speed-to-approval against evidence standards in the post-Prasad era. Companies, investors, and patient advocates should track these decisions closely.
-
Pancreatic cancer's treatment gap creates urgency. Theriva's advancement of VCN-01 into Phase 3 keeps oncolytic virotherapy in the spotlight for one of oncology's most challenging indications. With few viable options for metastatic PDAC patients, any Phase 3 readout will attract intense scrutiny — and potential partnership interest from large pharma.
-
Biosimilar momentum is accelerating. The dual denosumab biosimilar approvals this week are part of a broader trend: as major biologics age off patent protection, the FDA is clearing biosimilar pipelines at a meaningful pace. Investors should watch how launch pricing and payer uptake evolve for these newly approved entrants.
-
Real-world Alzheimer's data will shape lecanemab's commercial trajectory. The Eisai/Biogen AD/PD 2026 presentation on real-world Leqembi persistence is an early test of whether clinical trial enthusiasm translates into durable treatment in practice. Dropout rates, side effect management, and payer coverage decisions in this early data will influence future prescribing confidence.
Reader Action Items
-
If you're in biotech: Study the STAT News "post-Prasad FDA" framework carefully — the regulatory signals embedded in upcoming rare disease drug decisions will shape trial design and approval strategy for the next several years.
-
If you're an investor: The dual denosumab biosimilar approvals and Kelun-Biotech's growth results both signal that biosimilar and China-originated pipelines are increasingly competitive. Evaluate your exposure to innovator biologics facing biosimilar headwinds.
-
If you're a patient advocate: Real-world Leqembi data presented this week at AD/PD 2026 is worth following closely — it is among the first looks at how Alzheimer's patients are actually tolerating and persisting on the only approved amyloid-targeting therapy, with direct implications for access and support programs.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Create your own signal
Describe what you want to know, and AI will curate it for you automatically.
Create SignalPowered by
